Clinical Trial Update: Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma [Phase 3]

View source ↗

Summary

A phase 3 trial comparing talimogene laherparepvec to GM-CSF in melanoma reports efficacy and safety outcomes; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)
• Leukine (sargramostim)

Snippet

Sponsor: BioVex Limited | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2015-12-17